Claims for Patent: 7,368,264

Summary for Patent: 7,368,264

Title:	SLC1A1 marker for anxiety disorder
Abstract:	The present invention provides methods for diagnosing or identifying susceptibility of a subject to an anxiety or mood disorder. One method involves testing a sample obtained from the subject for the presence of a polymorphism in Intron 10 of the SLC1A1 gene. The presence of allele G or allele A of the A/G polymorphism rs301434 indicates that the patient is susceptible to an anxiety disorder. An alternate method involves testing a sample obtained from the subject for the presence of a polymorphism in the 3\' untranslated region of the SLC1A1 gene. The presence of allele C of C/G polymorphism rs3087879 indicates that the patient is susceptible to an anxiety disorder. Furthermore, a method is provided that involves testing a sample obtained from the subject for the presence of a haplotype in the SLC1A1 gene, wherein the combined presence allele G of the A/G polymorphism rs301434 and allele C of C/G polymorphism rs3087879 indicates that the patient is susceptible to a mood disorder.
Inventor(s):	Arnold; Paul Daniel (Toronto, CA), Richter; Margaret A. (Toronto, CA), Kennedy; James Lowery (Toronto, CA)
Assignee:	Centre for Addiction and Mental Health (Toronto, CA)
Application Number:	11/591,244
Patent Claims:	1. A method of diagnosing or identifying susceptibility of a subject to an anxiety disorder which comprises testing a sample obtained from the subject for the presence of a polymorphism or haplotype in Intron 10 of the SLC1A1 gene, wherein the presence of allele G of the A/G polymorphism rs301434 indicates that the subject is susceptible to an anxiety disorder. 2. The method of claim 1, wherein the sample is blood. 3. The method of claim 1, wherein the anxiety disorder is obsessive-compulsive disorder. 4. The method of claim 3, wherein the obsessive-compulsive disorder comprises aggressive obsessions, checking compulsions, symmetry obsessions, ordering compulsions, counting compulsions, repeating compulsions or a combination thereof. 5. The method of claim 1, wherein the step of testing comprises DNA extraction and PCR analysis. 6. A method of diagnosing or identifying susceptibility of a subject to an anxiety disorder which comprises testing a sample obtained from the subject for the presence of a polymorphism or haplotype in the SCL1A1 gene, wherein the presence of allele A of A/G polymorphism rs301435 indicates that the subject is susceptible to an anxiety disorder. 7. The method of claim 6, wherein the sample is blood. 8. The method of claim 6, wherein the anxiety disorder is obsessive-compulsive disorder. 9. The method of claim 8, wherein the obsessive-compulsive disorder comprises aggressive obsessions, checking compulsions, symmetry obsessions, ordering compulsions, counting compulsions, repeating compulsions or a combination thereof. 10. The method of claim 6, wherein the step of testing comprises DNA extraction and PCR analysis. 11. A method of diagnosing or identifying susceptibility of a subject to an anxiety disorder which comprises testing a sample obtained from the subject for the presence of a polymorphism or haplotype in the SCL1A1 gene, wherein the presence of allele C of C/G polymorphism rs3087879 indicates that the subject is susceptible to an anxiety disorder. 12. The method of claim 11, wherein the sample is blood. 13. The method of claim 11, wherein the anxiety disorder is obsessive-compulsive disorder. 14. The method of claim 13, wherein the obsessive-compulsive disorder comprises aggressive obsessions, checking compulsions, symmetry obsessions, ordering compulsions, counting compulsions, repeating compulsions or a combination thereof. 15. The method of claim 11, wherein the step of testing comprises DNA extraction and PCR analysis. 16. A method of diagnosing or identifying susceptibility of a subject to an anxiety disorder which comprises testing a sample obtained from the subject for the presence of a polymorphism or haplotype in the SCL1A1 gene, wherein the combined presence of allele G of the A/G polymorphism rs301434 and allele C of C/G polymorphism rs3087879 indicates that the subject is susceptible to an anxiety disorder. 17. The method of claim 16, wherein the sample is blood. 18. The method of claim 16, wherein the anxiety disorder is obsessive-compulsive disorder. 19. The method of claim 18, wherein the obsessive-compulsive disorder comprises aggressive obsessions, checking compulsions, symmetry obsessions, ordering compulsions, counting compulsions, repeating compulsions or a combination thereof. 20. The method of claim 16, wherein the step of testing comprises DNA extraction and PCR analysis.

Details for Patent 7,368,264

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2025-12-23
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2025-12-23
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2025-12-23